Medicaid & Pricing
CMS extends deadlines for Medicaid drug pricing model
By Intent.Health Team • April 30, 2026
What’s happening
The U.S. Centers for Medicare & Medicaid Services extended application deadlines for a Medicaid drug pricing model aimed at lowering prescription costs.
What’s changing / Business impact
-
More time for: states and drugmakers to join pricing program.
-
Expands potential participation in government price negotiation framework.
-
Signals continued push toward cost control at the Medicaid level.
Why this matters
Drug pricing pressure is expanding beyond Medicare → into Medicaid systems.
This shows:
-
Government pricing power is broadening across programs.
-
Pharma pricing strategies will face multi-layer pressure.
-
Cost control is becoming a system-wide priority.